You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLopinavir
Accession NumberDB01601  (EXPT00388)
TypeSmall Molecule
GroupsApproved
Description

Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.

Structure
Thumb
Synonyms
LPV
External Identifiers
  • A-157378-0
  • A-157378.0
  • ABT-378
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AluviranNot Available
KoletraNot Available
Brand mixtures
NameLabellerIngredients
KaletraAbb Vie Inc.
SaltsNot Available
Categories
UNII2494G1JF75
CAS number192725-17-0
WeightAverage: 628.8008
Monoisotopic: 628.362470666
Chemical FormulaC37H48N4O5
InChI KeyInChIKey=KJHKTHWMRKYKJE-SUGCFTRWSA-N
InChI
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
IUPAC Name
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES
CC(C)[[email protected]](N1CCCNC1=O)C(=O)N[[email protected]](C[[email protected]](O)[[email protected]](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenol ether
  • Pyrimidone
  • Alkyl aryl ether
  • Fatty acyl
  • Pyrimidine
  • N-acyl-amine
  • Fatty amide
  • 1,3-diazinane
  • Urea
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
PharmacodynamicsLopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.
Mechanism of actionLopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles.
Related Articles
AbsorptionAdministered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.
Volume of distributionNot Available
Protein bindingLopinavir is highly bound to plasma proteins (98-99%).
Metabolism

Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityAlthough human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6593
Blood Brain Barrier-0.9916
Caco-2 permeable+0.8856
P-glycoprotein substrateSubstrate0.8755
P-glycoprotein inhibitor IInhibitor0.7355
P-glycoprotein inhibitor IIInhibitor0.5277
Renal organic cation transporterNon-inhibitor0.8578
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6732
CYP450 1A2 substrateNon-inhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.7326
CYP450 2D6 inhibitorNon-inhibitor0.9438
CYP450 2C19 inhibitorNon-inhibitor0.7983
CYP450 3A4 inhibitorNon-inhibitor0.6469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9054
Ames testNon AMES toxic0.8049
CarcinogenicityNon-carcinogens0.7865
BiodegradationNot ready biodegradable0.9182
Rat acute toxicity2.2503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8605
hERG inhibition (predictor II)Inhibitor0.8475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral
Solutionoral
Tabletoral
Tablet, film coatedoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5914332 Yes1996-06-132016-06-13Us
US6037157 Yes1996-12-262016-12-26Us
US6232333 Yes1998-05-072018-05-07Us
US6284767 Yes1996-08-152016-08-15Us
US6458818 Yes1998-05-072018-05-07Us
US6521651 Yes1998-05-072018-05-07Us
US6703403 Yes1996-12-262016-12-26Us
US6911214 Yes2002-05-282022-05-28Us
US7141593 Yes2000-11-222020-11-22Us
US7148359 Yes2000-01-192020-01-19Us
US7364752 Yes2001-05-102021-05-10Us
US7432294 Yes2000-11-222020-11-22Us
US8025899 Yes2008-06-142028-06-14Us
US8268349 Yes2005-02-252025-02-25Us
US8309613 Yes2005-06-242025-06-24Us
US8377952 Yes2008-04-222028-04-22Us
US8399015 Yes2005-02-252025-02-25Us
US8470347 Yes2007-03-172027-03-17Us
US8501219 No2001-11-282021-11-28Us
US8691878 Yes2005-02-252025-02-25Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00192 mg/mLALOGPS
logP3.91ALOGPS
logP4.69ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)13.39ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area120 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity179.36 m3·mol-1ChemAxon
Polarizability69.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US5914332
General ReferencesNot Available
External Links
ATC CodesJ05AR10
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lopinavir.
AmiodaroneLopinavir may increase the QTc-prolonging activities of Amiodarone.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Lopinavir.
BatimastatThe serum concentration of Lopinavir can be increased when it is combined with Batimastat.
BepridilThe metabolism of Bepridil can be decreased when combined with Lopinavir.
BexaroteneThe serum concentration of Lopinavir can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Bortezomib can be increased when combined with Lopinavir.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Lopinavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lopinavir.
CarbamazepineThe serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Lopinavir.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lopinavir.
CitalopramCitalopram may increase the QTc-prolonging activities of Lopinavir.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Lopinavir.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Lopinavir.
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lopinavir.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Lopinavir.
DisulfiramThe risk or severity of adverse effects can be increased when Lopinavir is combined with Disulfiram.
DofetilideDofetilide may increase the QTc-prolonging activities of Lopinavir.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.
EfavirenzThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Lopinavir.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Lopinavir.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Lopinavir.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Lopinavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Lopinavir.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Lopinavir.
FosamprenavirThe serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.
FosphenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Fusidic Acid can be increased when it is combined with Lopinavir.
GarlicThe serum concentration of Lopinavir can be decreased when it is combined with Garlic.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Lopinavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lopinavir.
GoserelinGoserelin may increase the QTc-prolonging activities of Lopinavir.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Lopinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lopinavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lopinavir.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Lopinavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.
IsoflurophateThe serum concentration of Lopinavir can be increased when it is combined with Isoflurophate.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.
KetoconazoleThe serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lopinavir.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Lopinavir.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lopinavir.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Lopinavir.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.
MethadoneMethadone may increase the QTc-prolonging activities of Lopinavir.
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.
NelfinavirThe serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.
NevirapineThe serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.
NorethisteroneThe serum concentration of Norethindrone can be decreased when it is combined with Lopinavir.
OctreotideOctreotide may increase the QTc-prolonging activities of Lopinavir.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Lopinavir.
PhenobarbitalThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.
QuinidineLopinavir may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Lopinavir.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Lopinavir.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Lopinavir.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Lopinavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Lopinavir.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lopinavir.
SimeprevirThe serum concentration of Lopinavir can be increased when it is combined with Simeprevir.
St. John's WortThe metabolism of Lopinavir can be increased when combined with St. John's Wort.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lopinavir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Lopinavir.
TenofovirLopinavir may increase the nephrotoxic activities of Tenofovir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lopinavir.
TorasemideThe metabolism of Torasemide can be decreased when combined with Lopinavir.
TrazodoneLopinavir may increase the QTc-prolonging activities of Trazodone.
TriamcinoloneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Triamcinolone.
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Lopinavir.
VerapamilThe serum concentration of Lopinavir can be increased when it is combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lopinavir.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Lopinavir.
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
  2. Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM: Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007 Sep 6;50(18):4316-28. Epub 2007 Aug 16. [PubMed:17696512 ]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Authors unspecified: Lopinavir/ritonavir: a protease inhibitor combination. Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2. [PubMed:11151088 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4. [PubMed:12700464 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 12:45 / Updated on June 27, 2016 03:07